Angelini Pharma lures Gilead exec to be its new CEO

Italy-based privately-owned Angelini Industries has appointed Jacopo Andreose as chief executive (CEO) of its subsidiary Angelini Pharma, a position he will take up starting from February 6, 2023.

Mr Andreose has a wealth of experience in top roles within the pharmaceutical industry: he comes from Gilead Sciences (Nasdaq: GILD), where he held the role of senior vice president, Intercontinental Region, with direct responsibility for the business in Asia, Latin America, the Middle East, Africa, Eastern Europe. Previously, Mr Andreose worked at GlaxoSmithKline (LSE: GSK)/ViiV Healthcare, Bristol Myers Squibb and Abbott, covering growing strategic and operational roles in Italy, the USA, Europe and Asia.

“We are delighted to welcome Jacopo Andreose, who we have chosen for his extensive international experience and in-depth knowledge of the sector,” said Sergio Marullo di Condojanni and Thea Paola Angelini, respectively CEO and executive vice president of Angelini Industries, adding: “We are confident that Jacopo will make a significant contribution to the development and growth path of Angelini Pharma, which for over a century has prioritized the health and care of people.”